Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Amgen receives EC approval for Uplizna in generalised myasthenia gravis
Amgen has secured approval from the European Commission (EC) for Uplizna (inebilizumab) as an add-on treatment to standard therapy for …
-
Philips unveils new InkSpace Snuggle coil for paediatric imaging
Philips has introduced the InkSpace Imaging Snuggle flexible paediatric body array coil, designed for use with its 3.0T magnetic resonance …
-
Lyell doses first patient in Phase III trial for LBCL
Lyell Immunopharma has dosed the first patient in its PiNACLE – H2H Phase III chimeric antigen receptor (CAR)-cell trial for …
-
Natus Sensory acquires medical technology company TheraB Medical
Natus Sensory has purchased TheraB Medical, a US-based company specialising in neonatal wearable phototherapy devices. The acquisition aims to extend access …
-
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
MSD has received the US Food and Drug Administration (FDA) approval for Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial
Senti Biosciences has completed enrolment of patients in its Phase I clinical trial assessing SENTI-202 in adults with relapsed or …
-
Merck and Calla Lily partner to advance Callavid platform
Merck KGaA (Merck) and Calla Lily Clinical Care have announced a strategic partnership to advance Callavid, an intravaginal drug delivery …
-
BioRestorative concludes Phase II BRTX-100 trial enrolment for cLDD
BioRestorative Therapies has concluded patient enrolment in its Phase II study evaluating the efficacy and safety of BRTX-100 for chronic …
-
Insilico and CMS launch drug discovery collaborations for CNS diseases
Insilico Medicine has announced several AI drug discovery collaborations with China Medical System (CMS) across several projects in central nervous …
-
TransMedics receives IDE approval from FDA for OCS Heart trial
TransMedics Group has received full and unconditional investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) …
-
Veradermics concludes enrolment in second Phase III VDPHL01 trial
Veradermics has completed enrolment in its second pivotal Phase III clinical trial of VDPHL01 for male pattern hair loss treatment. The …
-
Takeda and Iambic announce $1.7bn deal to advance small molecule programmes
Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a …
-
Abbott reports positive VERITAS study results for AFib
Abbott has reported positive early data from the VERITAS study, evaluating its investigational Amulet 360 left atrial appendage (LAA) occluder, …
-
Genentech reports fenebrutinib Phase III results for PPMS
Roche’s Genentech has reported new data from the Phase III FENtrepid trial of fenebrutinib, an investigational Bruton’s tyrosine kinase inhibitor, …
-
Novartis starts construction on new research facility in San Diego, US
Novartis has commenced construction on its new global biomedical research centre in San Diego, California, US, aimed at expanding its …
